Save
Management of bowel obstruction in patients with ovarian cancer
ESGO eAcademy, Sahar Salehi, 213404
Palliative chemotherapy for ovarian cancer patients – what should we palliate?
ESGO eAcademy, Torbjørn Paulsen, 213403
Palliative chemotherapy for cervical and endometrial cancer – What is the evidence?
ESGO eAcademy, Torbjørn Paulsen, 213401
Palliative sedation -guidelines and practical tips
ESGO eAcademy, Staffan Lundström, 213397
Psychological support for dying patients
ESGO eAcademy, Vesna I. Kesic, 213393
Ureteral reconstruction and Urinary conduits
ESGO eAcademy, Luis M. Chiva, 209153
Bowel surgery 
ESGO eAcademy, David Cibula, 209152
Bowel preparation
ESGO eAcademy, Dimitrios Haidopoulos, 209151
Video Assisted Thoracoscopic Surgery (VATS)
ESGO eAcademy, Murat Gultekin, 209150
Stomach mobilization - resection - placement of J-tube
ESGO eAcademy, Jalid Sehouli, 209149
Dissection of Porta Hepatis, Celiac Trunk and Techniques for Cholecystectomy
ESGO eAcademy, Denis Querleu, 209148
Splenectomy and Distal Pancreatectomy
ESGO eAcademy, David Cibula, 209147
Diaphragm stripping - resection - repair
ESGO eAcademy, Anna Fagotti, 209146
Liver Mobilization & Cardio-Phrenic LND
ESGO eAcademy, Luis M. Chiva, 209145
Morbidity and postoperatieve outcome
ESGO eAcademy, Jalid Sehouli, 209144
Nutrition
ESGO eAcademy, Philippe Morice, 209143
Preoperative and Postoperative evaluation of the advanced ovarian cancer patient
ESGO eAcademy, Stephanie Suria, 209142
Modified posterior exenteration and Excision of the pouch of Douglas sparing the rectum
ESGO eAcademy, Philippe Morice, 209141
Pelvic and Paarotic llymphadenectomy
ESGO eAcademy, Denis Querleu, 209140
Evaluation of the extension of the disease
ESGO eAcademy, Anna Fagotti, 209139
Science of tissue management - energy and hemostats, stapplers, ednocutters
ESGO eAcademy, Dimitrios Haidopoulos, 209138
Surgery in advanced epithelial ovarian cancer - Quality control
ESGO eAcademy, Luis M. Chiva, 211211
The aim of cytoreduction in ovarian cancer surgery
ESGO eAcademy, Murat Gultekin, 209137
CURRENT AND FUTURE DIRECTIONS FOR GRANULOSA CELL TUMOUR MANAGEMENT
ESGO eAcademy, Isabelle Ray-Coquard, 202840
WHAT IS THE STATE-OF-THE-ART FOR OVARIAN GERM CELL TUMOURS?
ESGO eAcademy, Jalid Sehouli, 202839
HEREDITARY GYNAECOLOGICAL CANCERS: PREVENTION AND ROLE OF PROPHYLACTIC SURGERIES
ESGO eAcademy, Ranjit Manchanda, 202843
HOW CAN WE ELIMINATE DEATHS IN HIGH RISK GTN?
ESGO eAcademy, Michael Seckl, 202838
STATE OF ART IN SCREENING OF GYNAECOLOGICAL CANCERS
ESGO eAcademy, Murat Gultekin, 202842
RECENT DEVELOPMENTS IN GTD AND MOLAR PREGNANCIES
ESGO eAcademy, Leon Massuger, 202837
THE IMPACT OF HEALTHY LIFE STYLE AND OBESITY ON PREVENTION OF GYNAECOLOGICAL CANCERS
ESGO eAcademy, Maria Kyrgiou, 202841
LAPAROSCOPIC VERSUS OPEN TREATMENT OF ENDOMETRIAL CANCER IN ELDERLY WOMEN
ESGO eAcademy, Ignacio Zapardiel, 202833
PREDICTIVE MARKERS IN CERVICAL CANCER
ESGO eAcademy, Cornelis D de Kroon, 203136
ELDERLY PATIENTS UNDERGOING SURGERY FOR OVARIAN OR CERVICAL CANCER: PERI-OPERATIVE ASSESSMENT AND SURGICAL CHOICES
ESGO eAcademy, Dina Kurdiani, 202832
PREDICTIVE MARKERS IN OVARIAN CARCINOMA
ESGO eAcademy, Alexandra Leary, 202835
FRAILTY EVALUATION AND MEDICAL TREATMENT OF ELDERLY POPULATION WITH GYNAECOLOGICAL MALIGNANCIES
ESGO eAcademy, Annamaria Ferrero, 202831
PREDICTIVE MARKERS IN ENDOMETRIAL CARCINOMA
ESGO eAcademy, Xavier Matias-Guiu, 202834
SUPPORTIVE CARE FOR WOMEN WITH GYNAECOLOGIC CANCER RECEIVING EXTERNAL BEAM RADIOTHERAPY AND BRACHYTHERAPY
ESGO eAcademy, Alina Sturdza, 202830
SUPPORTIVE CARE IN GYNECOLOGIC CANCER PATIENTS RECEIVING MEDICAL TREATMENT
ESGO eAcademy, Jørn Herrstedt, 202829
PERIOPERATIVE SUPPORTIVE CARE IN GYNECOLOGIC CANCER PATIENTS
ESGO eAcademy, Felix Hilpert, 202828
CERVICAL ADENOCARCINOMA IB1 AFTER RADICAL HYSTERECTOMY, POSITIVE LYMPHNODES - EVALUATION OF PERIAORTIC NODES, ADJUVANT THERAPY, MANAGEMENT OF OVARIES
ESGO eAcademy, Sebastien Gouy, 202824
CASE 3: DISTANT METASTASES, ENDOCRINE THERAPY, CHEMOTHERAPY
ESGO eAcademy, Guenter Emons, 202827
PLATINUM ELIGIBLE RECURRENT OVARIAN CANCER
ESGO eAcademy, Cristiana Sessa, 202820
CERVICAL CANCER IB1, 2CM TUMOR DIAMETER: SLN BIOPSY, MANAGEMENT IN REGARD TO ABSENCE/PRESENCE OF METASTATIC DISEASE
ESGO eAcademy, Alexander W. Reinthaller, 202823
CASE 2: ADVANCED, METASTATIC, TREATMENT WITH RADIOTHERAPY AND CHEMOTHERAPY
ESGO eAcademy, Melanie Powell, 202826
RECURRENT OVARIAN CANCER - ROLE OF SURGERY
ESGO eAcademy, Philipp Harter, 202819
SURGICAL MANAGEMENT IN PRIMARY OVARIAN CANCER
ESGO eAcademy, Giovanni Aletti, 202818
CERVICAL CANCER STAGE IB1, 3CM TUMOR DIAMETER: EVALUATION OF LYMPH NODES, RISK FACTORS AND THERAPEUTIC MANAGEMENT
ESGO eAcademy, Remi Nout, 202822
CASE 1: ADVANCED ENDOMETRIAL CANCER, AMENABLE TO SURGICAL RESECTION, ROLE OF NEOADJUVANT CHEMOTHERAPY
ESGO eAcademy, Frederic Amant, 202825
CURRENT CLINICALLY MEANINGFUL ASPECTS IN HEREDITARY UTERINE CANCER INCLUDING LYNCH SYNDROME
ESGO eAcademy, Uzi Beller, 202814
THE IMMUNOTHERAPY STORY
ESGO eAcademy, Lana Kandalaft, 202817
CURRENT CLINICALLY MEANINGFUL ASPECTS AND IMPORTANCE OF GERMLINE AND SOMATIC MUTATIONS IN HEREDITARY OVARIAN CANCER
ESGO eAcademy, Pauline Wimberger, 202813
THE PARP-I STORY
ESGO eAcademy, Andres Poveda, 202816
CURRENT CLINICALLY MEANINGFUL ASPECTS AND IMPORTANCE OF GERMLINE AND SOMATIC MUTATIONS IN HEREDITARY BREAST CANCER
ESGO eAcademy, Jan Lubinski, 202812
SURGICAL TRAILS
ESGO eAcademy, Andreas Du Bois, 202815
A COMPARATIVE STUDY OF TWO FOLLOW-UP STRATEGIES FOLLOWING TREATMENT OF ENDOMETRIAL CANCER BETWEEN AN ITALIAN AND A UK CENTRE
ESGO eAcademy, Valentina Ghirardi, 203531
HOW TO ASSESS RESECTABILITY AT PRIMARY SURGERY?
ESGO eAcademy, Anna Fagotti, 202808
WHICH ROLE CAN PATIENT REPORTED OUTCOMES AND QUALITY OF LIFE HAVE IN CLINICAL TRIALS
ESGO eAcademy, Remi Nout, 202811
ANGIOGENESIS
ESGO eAcademy, Sandro Pignata, 202807
HOW TO INTEGRATE PATIENT REPORTED OUTCOME TOOLS IN THE EVERYDAY GYNAECOLOGICAL CANCER CLINIC
ESGO eAcademy, Galina Velikova, 202810
BRCA/HRD
ESGO eAcademy, Jonathan A Ledermann, 202806
OVERVIEW OF CURRENT DEVELOPMENTS IN MEASURING AND REPORTING PATIENT REPORTED OUTCOMES AND QUALITY OF LIFE IN GYNAECOLOGICAL CANCER
ESGO eAcademy, Lonneke van de Poll-Franse, 202809
MANAGEMENT OF RECURRENT DISEASE
ESGO eAcademy, Frederic Amant, 202799
CERVICAL CANCER IMMUNOTHERAPY TRIAL
ESGO eAcademy, Hans Nijman, 202804
CONSERVATIVE TREATMENT OF ENDOMETRIAL CANCER IN YOUNG WOMEN
ESGO eAcademy, Dimitrios Haidopoulos, 202798
OVARIAN CANCER IMMUNOTHERAPY TRIALS
ESGO eAcademy, Jonathan A Ledermann, 202803
RADICAL TREATMENT OF ENDOMETRIAL CANCER IN YOUNG WOMEN
ESGO eAcademy, Nicoletta Colombo, 202797
RISK FACTORS AND PATHOGENESIS OF ENDOMETRIAL CANCER IN YOUNG WOMEN
ESGO eAcademy, Vesna Kesic, 202796
PRINCIPLES OF IMMUNOTHERAPY
ESGO eAcademy, Christian Marth, 202801
ONCOLOGICAL MANAGEMENT AND PREGNANCY OUTCOMES IN WOMEN DIAGNOSED WITH CANCER DURING PREGNANCY: A 20-YEAR INTERNATIONAL COHORT STUDY OF 1170 PATIENTS
ESGO eAcademy, Frederic Amant, 202790
MECHANISMS OF RESISTANCE IN BRCA MUTATED TUMORS
ESGO eAcademy, Clare Scott, 202793
QUALITY OF LIFE WITH WEEKLY, DOSE-DENSE VERSUS STANDARD CHEMOTHERAPY FOR OVARIAN CANCER IN THE ICON8 STUDY
ESGO eAcademy, Sarah Blagden, 202788
CLINICALLY SIGNIFICANT LONG-TERM MAINTENANCE TREATMENT WITH OLAPARIB IN PATIENTS WITH PLATINUM-SENSITIVE RELAPSED SEROUS OVARIAN CANCER (PSR SOC)
ESGO eAcademy, Charlie Gourley, 202787
CLINICAL DEVELOPMENT OF OTHER NON PARP TARGETED THERAPIES
ESGO eAcademy, Cristiana Sessa, 202792
HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) FOR OVARIAN CANCER
ESGO eAcademy, Willemien J. Van Driel, 202786
ARIEL3: PHASE 3, RANDOMISED, DOUBLE-BLIND STUDY OF RUCAPARIB VS PLACEBO FOLLOWING RESPONSE TO PLATINUM-BASED CHEMOTHERAPY FOR RECURRENT OVARIAN CARCINOMA (OC)
ESGO eAcademy, Jonathan A Ledermann, 202785
UPDATE ON THE CLINICAL DEVELOPMENT OF PARP INHIBITORS
ESGO eAcademy, Iain McNeish, 202791
CLINICAL TRIALS IN PLATINUM-RESISTANT DISEASE
ESGO eAcademy, Mansoor Mirza, 202781
STRATEGIES FOR OVERCOMING RESISTANCE TO CHEMOTHERAPY
ESGO eAcademy, Sandro Pignata, 202780
PLATINUM-RESISTANT DISEASE: CURRENT STATUS
ESGO eAcademy, Nicole Concin, 202779
RANKL -BONES, SEX, AND BREAST CANCER
ESGO eAcademy, Josef Penninger, 202794
WHY ARE WE FAILING TO CURE OVARIAN CANCER?"
ESGO eAcademy, Christian Marth, 202795
GENERAL IMPLEMENTATION OF IGABT (TRAINING/ MEANS/HEALTH ECONOMICS/RESOURCE LIMITATIONS)
ESGO eAcademy, Christine Haie-Meder, 202775
WHEN, WHY AND HOW TO TEST MISMATCH REPAIR DEFICIENCY IN ENDOMETRIAL CANCER
ESGO eAcademy, Tjalling Bosse, 202778
IMAGE-GUIDED ADAPTIVE BRACHYTHERAPY VERSUS IMRT/STEREOTACTIC RADIOTHERAPY
ESGO eAcademy, Akila Viswanathan, 202774
WHEN, WHY AND HOW TO TEST FOR L1CAM AND P53 EXPRESSION IN ENDOMETRIAL CANCER
ESGO eAcademy, Alain G. Zeimet, 202777
CURRENT STATUS OF IMAGE-GUIDED BRACHYTHERAPY : ONCOLOGICAL RESULTS AND COMPLICATIONS
ESGO eAcademy, Jacob Lindegaard, 202773
WHEN, WHY AND HOW TO TEST POLE MUTATIONAL STATUS IN ENDOMETRIAL CANCER
ESGO eAcademy, David Church, 202776
TREATMENT OF ADVANCED DISEASE, INCLUDING MANAGEMENT OF MORBIDITY
ESGO eAcademy, Alexandra Taylor, 202769
IMPACT OF VAGINAL MORBIDITY ON SEXUALITY AFTER DEFINITIVE RADIOCHEMOTHERAPY IN LOCALLY ADVANCED CERVICAL CANCER PATIENTS
ESGO eAcademy, Kathrin Kirchheiner, 202772
ADJUVANT TREATMENT
ESGO eAcademy, Carien Creutzberg, 202768
PHYSICAL CONSEQUENCES OF GYNAECOLOGIC CANCER SURGERY AND THEIR IMPACT ON SEXUAL HEALTH
ESGO eAcademy, Michal Zikan, 202771
DIAGNOSTIC AND SURGICAL MANAGEMENT
ESGO eAcademy, Philippe Morice, 202767
SEXUAL HEALTH IN GYNAECOLOGIC CANCER PATIENTS - PSYCHO-SOCIAL CONSEQUENCES OF DIAGNOSIS AND TREATMENT
ESGO eAcademy, Moniek M ter Kuile, 202770
Discussion and Closing
ESGO eAcademy, Sandro Pignata, 202898
Future therapies
ESGO eAcademy, Kathleen Moore, 202897
Adjuvant management
ESGO eAcademy, Nicoletta Colombo, 202896
Primary debulking strategy
ESGO eAcademy, Sven Mahner, 202895
Front-line Ovarian Cancer: Can we do better?: Welcome and introduction
ESGO eAcademy, Sandro Pignata, 202766
PERIOPERATIVE CARE OF THE ELDERLY PATIENT
ESGO eAcademy, Karl Tamussino, 202765
MANAGEMENT OF ADVANCED STAGES AND RECURRENT DISEASE
ESGO eAcademy, Richard Poetter, 202761

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings